Pfizer signs potential $10.5bn oncology licencing deal with China’s Innovent | FinanceAsia

US pharmaceutical giant Pfizer has entered into a global licencing agreement with Innovent Biologics (Innovent), a Chinese biopharmaceutical company listed on the Hong Kong Stock Exchange (HKEX), with the aim of accelerating the development of innovative oncology medicines, according to a May 28 announcement.

Also Read

A New Lease of Life for Expired Payment Cards – The European Financial Review

Barclays, Lloyds Back UK Finance Digital ID Service — Finance Monthly

PwC, OpenAI Prep AI Treasury Agents

Plugin developed by ProSEOBlogger. Get free gpl themes.

¬ Haymarket Media Limited. All rights reserved.